Stellabody: A novel hexamer‐promoting mutation for improved IgG potency
Immunological Reviews · 2024
DOI: 10.1111/imr.13400 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2024. Verfasst von Clarissa A Whitehead und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoglobulin G, Protein Engineering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Estate of Phyllis Schumann, Medical Research Future Fund (MRFF), Margaret Walkom bequest.
Abstract (Originalsprache)
Advances in antibody engineering are being directed at the development of next generation immunotherapeutics with improved potency. Hexamerisation of IgG is a normal physiological aspect of IgG biology and recently described mutations that facilitate this process have a substantial impact upon monoclonal antibody behavior resulting in the elicitation of dramatically enhanced complement‐dependent cytotoxicity, Fc receptor function, and enhanced antigen binding effects, such as targeted receptor agonism or microbe neutralization. Whereas the discovery of IgG hexamerisation enhancing mutations has largely focused on residues with exposure at the surface of the Fc‐Fc and CH2‐CH3 interfaces, our unique approach is the engineering of the mostly buried residue H429 in the CH3 domain. Selective substitution at position 429 forms the basis of Stellabody technology, where the choice of amino acid results in distinct hexamerisation outcomes. H429F results in monomeric IgG that hexamerises after target binding, so called “on‐target” hexamerisation, while the H429Y mutant forms pH‐sensitive hexamers in‐solution prior to antigen binding. Moreover, Stellabody technologies are broadly applicable across the family of antibody‐based biologic therapeutics, including conventional mAbs, bispecific mAbs, and Ig‐like biologics such as Fc‐fusions, with applications in diverse diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.
- Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- Randall Centre for Cell and Molecular Biophysics, King's College London, New Hunt's House, London, UK.
- Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Bruce D Wines, P Mark Hogarth
Förderung
- Estate of Phyllis Schumann
- Medical Research Future Fund (MRFF)
- Margaret Walkom bequest
- Victorian State Government
Zitieren
APA
Whitehead, C. A., Wines, B. D., Davies, A. M., McDonnell, J. M., Trist, H. M., Esparon, S. E., & Hogarth, P. M. (2024). Stellabody: A novel hexamer‐promoting mutation for improved IgG potency. Immunological Reviews. https://doi.org/10.1111/imr.13400
Vancouver
Whitehead CA, Wines BD, Davies AM, McDonnell JM, Trist HM, Esparon SE, et al. Stellabody: A novel hexamer‐promoting mutation for improved IgG potency. Immunological Reviews. 2024. doi:10.1111/imr.13400
BibTeX
@article{Whitehead2024,
author = {Whitehead, Clarissa A and Wines, Bruce D and Davies, Anna M and McDonnell, James M and Trist, Halina M and Esparon, Sandra E and Hogarth, P Mark},
title = {Stellabody: A novel hexamer‐promoting mutation for improved IgG potency},
journal = {Immunological Reviews},
year = {2024},
doi = {10.1111/imr.13400}
}
EUVIMED